Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $186 | $102 | $0 | $0 |
| % Growth | 82.4% | – | – | – |
| Cost of Goods Sold | $12 | $69 | $1,440 | $1,520 |
| Gross Profit | $174 | $33 | -$1,440 | -$1,520 |
| % Margin | 93.5% | 32.4% | – | – |
| R&D Expenses | $3,313 | $4,668 | $18,928 | $20,773 |
| G&A Expenses | $3,088 | $5,707 | $10,337 | $9,665 |
| SG&A Expenses | $3,198 | $6,250 | $10,563 | $9,995 |
| Sales & Mktg Exp. | $78 | $215 | $239 | $434 |
| Other Operating Expenses | -$479 | -$2,428 | -$9,002 | -$3,529 |
| Operating Expenses | $6,032 | $8,490 | $20,263 | $26,909 |
| Operating Income | -$5,858 | -$8,457 | -$40,857 | -$26,391 |
| % Margin | -3,149.5% | -8,291.2% | – | – |
| Other Income/Exp. Net | $34 | -$182 | -$13 | -$111 |
| Pre-Tax Income | -$5,824 | -$8,639 | -$40,870 | -$26,502 |
| Tax Expense | $0 | -$191 | $65 | $10 |
| Net Income | -$5,824 | -$8,448 | -$40,935 | -$26,512 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| Weighted Avg Shares Out | 41,429 | 25,722 | 22,594 | 15,604 |
| Weighted Avg Shares Out Dil | 41,429 | 25,722 | 22,594 | 15,604 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34 | $30 | $12 | $27 |
| Interest Expense | $0 | $84 | $197 | $255 |
| Depreciation & Amortization | $183 | $794 | $1,440 | $1,520 |
| EBITDA | -$5,687 | -$7,763 | -$39,695 | -$25,414 |
| % Margin | -3,057.5% | -7,610.8% | – | – |